SHAREHOLDER ALERT: Hims & Hers Health, Inc. Sued For Securities Fraud by Block & Leviton LLP; August 25 Deadline To Seek To Serve As Lead Plaintiff

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly violating federal securities laws by making false and misleading statements regarding the company's business and operations [1][2]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Hims & Hers made false statements about a collaboration with Novo Nordisk that would ensure continued access to the weight-loss drug Wegovy for its subscribers [2]. - It is alleged that Hims & Hers misrepresented that Novo approved its offerings of compounded semaglutide products under a "personalization" exception [2]. - The suit contends that Hims & Hers falsely indicated that branded Wegovy would be available alongside compounded semaglutide options, thereby misleading investors about user choice [2]. - Positive statements regarding the partnership with Novo and ongoing access to Wegovy were also allegedly made, which contributed to the decline in the company's stock value [2]. Group 2: Legal Proceedings - The lawsuit was filed in the Northern District of California and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05321 (N.D. Cal.) [3]. - The class action is on behalf of all individuals who purchased Hims & Hers common stock between April 29, 2025, and June 23, 2025 [3]. Group 3: Class Member Information - Investors who acquired Hims & Hers stock during the specified class period may seek to be appointed as lead plaintiffs, with a deadline to do so by August 25, 2025 [4]. - It is noted that investors do not need to be lead plaintiffs to participate in any potential recovery from the lawsuit [5].